A clinical-stage imaging developer funded in short steps

Imagion Biosystems Limited (ASX:IBX) is a Melbourne-based clinical-stage medical imaging company, and its recent announcements point to a Business that has reached the US regulatory stage while relying on convertible notes and small placements to stay funded. That pairing is the central theme here. No cash or burn figures could be verified for this article, which is why it is flagged.

What the company does

Imagion develops MagSense, an MRI imaging agent that uses non-radioactive, bio-safe magnetic nanoparticles. The company's stated aim is earlier and more specific cancer detection, with target applications in HER2-positive breast cancer, prostate cancer and ovarian cancer. It has no approved product, and clinical progress should not be confused with regulatory approval.

Regulatory milestone

On 2 February 2026, Imagion announced that it had lodged an Investigational New Drug (IND) application with the US Food and Drug Administration for a Phase 2 trial of the MagSense HER2 imaging agent. The FDA has 30 days to respond with questions or comments, and enrolment is expected to open only after FDA clearance. The company described a three-part study: an initial safety cohort, a cohort testing a reduced dose and optimised imaging protocol, and a larger cohort to establish diagnostic performance. It expected the trial to take 18 to 24 months from FDA acceptance. Those timings are company guidance. The outcome of the FDA review was not found in the sources reviewed, and an 8 April 2026 funding announcement still referred to Imagion awaiting the FDA's review.

Funding and dilution

Imagion has funded itself through a convertible securities agreement with Mercer Street Global Opportunity Fund, LLC, dated around March 2023 and amended several times. On 8 January 2026 it issued 3,048,484 shares on conversion of the remaining first-tranche notes, extinguishing a $1,650,000 note. The second Tranche was amended, with $300,000 due by 8 January and the remaining balance of $558,000 extended to 28 February 2026.

On 8 April 2026 the company announced an additional $300,000 of short-term funding from an Investment fund managed by C/M Capital Partners, an affiliate of Mercer Street. Notes previously due before 8 April were extended to mature on 31 December 2026, and new notes mature 18 months after issue with a floor price of $0.025. The company also lodged cleansing notices in September 2026 for 40,208,334 listed options expiring 13 December 2027, following a Placement announced on 25 June 2026. Details of the placement size and price were not reviewed.

Taken together, these steps show repeated small financings and conversions, which are a source of dilution for shareholders. The company's latest quarterly cash balance and funding estimate were not available to this review and should be checked in its Appendix 4C.

Risks

Risks include the usual clinical-stage uncertainties: regulatory outcomes, trial recruitment, diagnostic performance and the time needed to reach any commercial use. Funding risk is also relevant given reliance on convertible notes and placements. A note Maturity date of 31 December 2026 is a dated item to watch, although the filings do not say how it will be settled.